←Back to News & Press releases

Airsonett Air4 provides a clinical improvement in Quality of Life within 3 months of treatment

January 11, 2019

An independent time to onset (TTO) study, using the Airsonett Air4 Temperature-controlled Laminar Airflow technology (TLA), by Professor Leif Bjermer (Department of Respiratory and Allergology, University Hospital Lund, Sweden), concludes that Nocturnal treatment with TLA provided a statistically significant and clinically relevant improvement in total Quality of Life score (AQLQ) within 3 months in patients with poorly controlled asthma. Questions related to sleep quality may provide the first signal of response already within a month after commencing treatment.

“Allergen elimination is one of the cornerstones in asthma management. The rapid response to treatment is important from a clinical perspective allowing firm conclusions already after a short test period. This is highly appreciated” says Leif Bjermer, Professor Department of Respiratory and Allergology, University Hospital Lund, Sweden.

“We had previous indications that the clinical effects of the TLA technology were evident within 3-6 months. Having this now documented at three months as well as one month for sleep is fantastic” says Anders Due-Boje, CEO Airsonett AB.

For the full article in Respiratory Medicine, please visit:

https://www.sciencedirect.com/science/article/pii/S0954611118303950?dgcid=coauthor


About severe, uncontrolled asthma

Patients with severe, uncontrolled asthma treated according to Global Initiative for Asthma (GINA) step 4/5 account for approximately 3% of all patients with persistent asthma, according to recent population-based studies using administrative and prescribed databases, but account for a much larger share of asthma-related healthcare resource use and costs. Treatment alternatives for such patients include high-dose inhaled corticosteroids (ICS) and long-acting β2-antagonists (LABAs) and/or systematic corticosteroids. During the last decade, several new drugs for the treatment of severe asthma have been developed,and some of these drugs, such as anti-immunoglobulin E and anti-interleukin 5 have been included in Step 5 in the latest GINA recommendations. The costs for treatment with these biologics are however very high. Temperature-controlled laminar airflow (TLA) is a relatively new treatment for patients with severe, uncontrolled asthma. The use of TLA has shown cost-effectiveness according to National Institute for Health and Care Excellence (NICE) standards and the Swedish Dental and Pharmaceutical Benefits Agency, TLV, a central government agency whose remit is to determine whether a pharmaceutical product, medical device or dental care procedure shall be subsidized by the state.

Download the press release as pdf.

For more information:

Anders Due-Boje, CEO, Airsonett AB
Tel: +46 70 526 03 00
E-mail: anders.due-boje@airsonett.eu